PriceTargets.com logo

Renalytix - RNLX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 523.44%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.80 As of 04/19/2024 01:00 AM ET
▲ +0.02 (2.56%)

This chart shows the closing price for RNLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Renalytix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RNLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RNLX

Analyst Price Target is $5.00
▲ +523.44% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Renalytix in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 523.44% upside from the last price of $0.80.

This chart shows the closing price for RNLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Renalytix. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/30/2023HC WainwrightReiterated RatingBuy ➝ Buy$5.00Low
6/30/2023BTIG ResearchBoost Target$3.50 ➝ $5.00Low
6/9/2023Stifel NicolausLower Target$6.00 ➝ $5.00Low
4/3/2023BTIG ResearchLower TargetBuy$4.00 ➝ $3.50Low
4/3/2023HC WainwrightLower TargetBuy$8.00 ➝ $5.00Low
12/2/2022HC WainwrightLower TargetBuy$10.00 ➝ $8.00Low
11/1/2022HC WainwrightLower TargetBuy$15.00 ➝ $10.00Low
7/1/2022BTIG ResearchLower TargetBuy$15.00 ➝ $5.00Low
7/1/2022Stifel NicolausLower TargetBuy$17.00 ➝ $7.00Low
7/1/2022HC WainwrightLower TargetBuy$30.00 ➝ $15.00Low
4/1/2022BTIG ResearchLower TargetBuy$24.00 ➝ $15.00Low
4/1/2022JPMorgan Chase & Co.Lower Target$25.00 ➝ $8.00Low
4/1/2022HC WainwrightReiterated RatingBuy$30.00High
1/18/2022HC WainwrightInitiated CoverageBuy$30.00High
1/4/2022BTIG ResearchInitiated CoverageBuy$24.00High
10/4/2021GuggenheimInitiated CoverageBuy$28.00Medium
7/2/2021Berenberg BankInitiated CoverageBuy$38.00High
4/22/2021InvestecUpgradeHold ➝ BuyHigh
3/2/2021InvestecDowngradeBuy ➝ HoldLow
8/11/2020JPMorgan Chase & Co.Initiated CoverageNeutralHigh
8/11/2020Stifel NicolausInitiated CoverageBuy$22.00High
(Data available from 4/19/2019 forward)

News Sentiment Rating

-0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Renalytix logo
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.
Read More

Today's Range

Now: $0.80
Low: $0.77
High: $0.81

50 Day Range

MA: $0.93
Low: $0.67
High: $1.47

52 Week Range

Now: $0.80
Low: $0.24
High: $4.04

Volume

30,126 shs

Average Volume

1,633,662 shs

Market Capitalization

$40.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Renalytix?

The following sell-side analysts have issued reports on Renalytix in the last year: BTIG Research, HC Wainwright, and Stifel Nicolaus.
View the latest analyst ratings for RNLX.

What is the current price target for Renalytix?

3 Wall Street analysts have set twelve-month price targets for Renalytix in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 523.4%. Stifel Nicolaus has the highest price target set, predicting RNLX will reach $5.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $5.00 for Renalytix in the next year.
View the latest price targets for RNLX.

What is the current consensus analyst rating for Renalytix?

Renalytix currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RNLX will outperform the market and that investors should add to their positions of Renalytix.
View the latest ratings for RNLX.

What other companies compete with Renalytix?

Other companies that are similar to Renalytix include Cutera, Energem, Quantum, IZEA Worldwide and iCAD. Learn More about companies similar to Renalytix.

How do I contact Renalytix's investor relations team?

Renalytix's physical mailing address is AVON HOUSE 19 STANWELL ROAD PENARTH, CARDITH X0, CF64 2EZ. The company's listed phone number is 44-20-3139-2910 and its investor relations email address is [email protected]. The official website for Renalytix is www.renalytixai.com. Learn More about contacing Renalytix investor relations.